Skip to main content
Evidence Snapshot

Peroxisome proliferator-activated receptor gamma

CHEMBL2459 SINGLE PROTEIN Mus musculus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T06:45:28Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2459
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Peroxisome proliferator-activated receptor gamma as ChEMBL target CHEMBL2459, mapped to UniProt P37238. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Peroxisome proliferator-activated receptor gamma
SINGLE PROTEIN · Mus musculus
As of 2026-09-13
ChEMBL target ID
CHEMBL2459
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P37238
Peroxisome proliferator-activated receptor gamma
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Peroxisome proliferator-activated receptor gamma matters

As of 2026-09-13

Peroxisome proliferator-activated receptor gamma is reviewed as Peroxisome proliferator-activated receptor gamma (UniProt P37238); the current evidence base includes 5 approved drugs, 448 compounds, and 259 assays, with lead potency reaching pChEMBL 9.8.

Protein context
Peroxisome proliferator-activated receptor gamma

Peroxisome proliferator-activated receptor gamma Sequence length is 505 aa.

Review this target as Peroxisome proliferator-activated receptor gamma, mapped to UniProt P37238. Sequence length is 505 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P37238 Protein
Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 5 approved drugs, 448 compounds, and 259 assays for this target. The dominant activity type is EC50. CHEMBL5207130 is the current potency anchor at pChEMBL 9.8.

Use CHEMBL5207130 as the tractability anchor when discussing potency (pChEMBL 9.8).

Activity source · ChEMBL 36 via Core Engine
5 approved pChEMBL 9.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Peroxisome proliferator-activated receptor gamma matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P37238, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

448
Total Compounds
259
Total Assays
5
Approved Drugs
IC50: 15.0, KI: 1.0, EC50: 271.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5207130
9.8 IC50
No preferred name
CHEMBL107367
9.5 EC50 Clinical
No preferred name
CHEMBL106666
8.9 EC50
No preferred name
CHEMBL602468
8.7 EC50
No preferred name
CHEMBL3115237
8.5 EC50

Approved Drugs

Structure Compound First Approval
ROSIGLITAZONE
CHEMBL121
1999
PIOGLITAZONE
CHEMBL595
1999
TROGLITAZONE
CHEMBL408
1997
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T06:45:28Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2459